New drug may offer safer option for Hormone-Driven high blood pressure
NCT ID NCT07688928
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests whether a newer drug, finerenone, works better and is safer than the standard drug spironolactone for people with high blood pressure due to primary aldosteronism—a condition where the adrenal glands make too much of the hormone aldosterone. About 104 adults with this condition will receive either finerenone or spironolactone for 48 weeks, with doses adjusted to reach target blood pressure and hormone levels. The trial measures how quickly and at what dose each drug achieves control, along with effects on kidney function, heart structure, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Finerenone
- What this could lead to
- If finerenone works better or has fewer side effects than spironolactone, it could become a new standard treatment for primary aldosteronism.
- What could go wrong
- This is a single-center trial with 104 participants, so results may not apply broadly. Both drugs can cause high potassium levels or kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOCRINE HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Endocrine HTN Clinic
RECRUITINGDhaka, 1000, Bangladesh
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New scan could replace risky vein test for Hormone-Driven high blood pressure
- New screening strategy could speed diagnosis of inherited aldosteronism
- Alcohol injection into adrenal tumors may offer surgery-free blood pressure control
- Sharper blood test could uncover hidden cause of high blood pressure
- Tighter blood pressure target may slash heart risks in hormone disorder
- Could hidden hormone cycles be causing Hard-to-Treat high blood pressure?